Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 11,893	$ 14,025
Accounts receivable, net of allowance for credit losses	2,971	1,906
Contract assets	2,689	1,604
Inventories	4,925	4,454
Other current assets	858	852
Total current assets	23,336	22,841
Property, plant and equipment, net	12,089	12,166
Other assets	18	18
Total assets	35,443	35,025
Current liabilities:
Accounts payable	1,798	1,203
Accrued expenses	1,690	1,765
Current maturities of long-term debt	83	81
Deposit from purchaser of MesoScribe assets-Note 11	597	597
Contract liabilities	6,030	4,908
Total current liabilities	10,198	8,554
Long-term debt, net of current portion	247	268
Total liabilities	10,445	8,822
Contingencies – Note 12
Stockholders’ equity:
Common stock - $0.01 par value – 20,000,000 shares authorized; 6,824,511 issued and outstanding at March 31, 2024 and December 31, 2023	68	68
Additional paid-in capital	28,962	28,695
Accumulated deficit	(4,032)	(2,560)
Total stockholders’ equity	24,998	26,203
Total liabilities and stockholders’ equity	$ 35,443	$ 35,025